GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heart Test Laboratories Inc (NAS:HSCS) » Definitions » Net-Net Working Capital

Heart Test Laboratories (Heart Test Laboratories) Net-Net Working Capital : $8.26 (As of Jan. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Heart Test Laboratories Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Heart Test Laboratories's Net-Net Working Capital for the quarter that ended in Jan. 2024 was $8.26.

The industry rank for Heart Test Laboratories's Net-Net Working Capital or its related term are showing as below:

HSCS's Price-to-Net-Net-Working-Capital is ranked better than
96.42% of 447 companies
in the Medical Devices & Instruments industry
Industry Median: 6.23 vs HSCS: 0.71

Heart Test Laboratories Net-Net Working Capital Historical Data

The historical data trend for Heart Test Laboratories's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heart Test Laboratories Net-Net Working Capital Chart

Heart Test Laboratories Annual Data
Trend Apr20 Apr21 Apr22 Apr23
Net-Net Working Capital
-8.93 -34.23 -84.92 -10.47

Heart Test Laboratories Quarterly Data
Apr20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.59 -10.47 -20.65 -31.90 8.26

Competitive Comparison of Heart Test Laboratories's Net-Net Working Capital

For the Medical Devices subindustry, Heart Test Laboratories's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heart Test Laboratories's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Heart Test Laboratories's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Heart Test Laboratories's Price-to-Net-Net-Working-Capital falls into.



Heart Test Laboratories Net-Net Working Capital Calculation

Heart Test Laboratories's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Apr. 2023 is calculated as

Net-Net Working Capital(A: Apr. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1.66+0.75 * 0+0.5 * 0.676-3.057
-0-0)/0.10118
=-10.47

Heart Test Laboratories's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jan. 2024 is calculated as

Net-Net Working Capital(Q: Jan. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(7.076+0.75 * 0.015+0.5 * 0.67-2.167
-0-0)/0.63612
=8.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Heart Test Laboratories  (NAS:HSCS) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Heart Test Laboratories Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Heart Test Laboratories's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Heart Test Laboratories (Heart Test Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
Heart Test Laboratories Inc is a medical technology company focused on applying innovative AI-based technology to an ECG to expand and improve an ECG's clinical usefulness. The objective of the company is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings.
Executives
David R. Wells director 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Bruce Bent director 750 BONHAM PARKWAY, LANTANA TX 76226
Mark T Hilz director, officer: See Remarks 3301 DAKOTA DRIVE, NORTHLAKE TX 76226
Patrick Kanouff director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Brian Szymczak director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Danielle Watson officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Andrew Simpson director, officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092